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Abstract: The prevalence of malnutrition in patients with cancer has frequently been shown 
to be one of the highest of all hospital patient groups. Weight loss is a frequent 
manifestation of malnutrition in patients with cancer. Several large-scale studies over the 
last 35 years have reported that involuntary weight loss affects 50-80% of these patients 
with the degree of weight loss dependent on tumour site, type and stage of disease. This 
review will focus on the consequences of malnutrition, weight loss and muscle wasting in 
relation to chemotherapy tolerance, post-operative complications, quality of life and 
survival in oncology patients. 
The prognostic impact of weight loss on overall survival has long been recognised with 
recent data suggesting losses as little as 2.4% predicts survival independent of disease, site, 
stage or performance score. Recently the use of gold-standard methods of body 
composition assessment, including computed tomography, have led to an increased 
understanding of the importance of muscle abnormalities, such as low muscle mass 
(sarcopenia), and more recently low muscle attenuation, as important prognostic indicators 
of unfavourable outcomes in patients with cancer. Muscle abnormalities are highly 
prevalent (ranging from 10-90%, depending on cancer site and the diagnostic criteria used). 
Both low muscle mass and low muscle attenuation have been associated with poorer 
tolerance to chemotherapy; increased risk of postoperative complications; significant 
deterioration in a patients' performance status, and poorer psychological well-being, overall 















The prevalence of malnutrition in patients with cancer has frequently been shown to 
be one of the highest of all patient groups(1; 2; 3). Weight loss is a frequent manifestation of 
malnutrition and is an important criterion included in several malnutrition screening tools 
commonly used in clinical settings.  Several large scale studies over the last 35 years have 
reported that involuntary weight loss affects 50-80% of patients with cancer with the 
degree of weight loss dependent on tumour site, type and stage of disease(4; 5; 6).   
The prognostic impact of weight loss on overall survival has long been recognised 
with recent data suggesting ongoing weight loss of more than 2.4% predicts survival, 
independent of disease site, stage or performance score(6). In addition to the adverse impact 
on survival, weight loss has been associated with severe chemotherapy-related toxicity(7; 8; 
9);and leads to a significant deterioration in a patients’ performance status, psychological 
well-being and overall quality of life(10). 
 
Causes of nutritional deterioration in cancer 
Nutritional deterioration has unfortunately become an accepted part of the 
pathogenesis of cancer and its treatment(11). Changes in nutrition status can occur at any 
point in the timeline of a cancer diagnosis, treatment, or support. The degree of 
malnutrition that occurs is affected by cancer type, stage and therapy modality; however, 
the etiology of cancer-induced weight loss and malnutrition is both multifactorial and 
complex. The form of malnutrition that occurs in malignancy is particularly challenging to 
address as it is not driven by simple starvation but occurs secondary to a negative energy 
balance caused by the detrimental combination of reduced oral intake and metabolic 
derangements unique to cancer(12; 13).    
Cancer-associated malnutrition can occur as a result of poor oral intake, mechanical 
or physiological changes to the gut, side effects of treatment, or metabolic abnormalities 
caused by the tumour. Both the quantity and the quality of dietary intake can be 
significantly altered due any one of a number of factors including: dysphagia, nausea, 
changes in taste and smell, pain, early satiety or fatigue. In addition to this, the presence of 
cancer in the body causes a variety of metabolic and endocrine changes (such as 
inflammation, anabolic resistance, proteolysis, lipolysis and futile cycling) induced by the 













inflammatory cytokines), neuro-hormonal changes, and potential proteolytic and lipolytic 
factors produced by the host and the tumour, fuel weight loss and loss of lean mass(13).  
 
Weight loss and changes in body composition following a cancer diagnosis 
Involuntary weight loss is a hallmark feature of cancer-associated malnutrition and 
can lead to cancer cachexia; a multifactorial syndrome characterised by the ongoing loss of 
skeletal muscle mass (with or without loss of fat mass) that cannot be fully reversed by 
conventional nutrition support(14). It is a condition characterised by a negative protein and 
energy balance driven by a variable combination of reduced food intake and abnormal 
metabolism(14).  Studies dating back over the past 35 years have reported that moderate-to-
severe weight loss is present in 30-70% of cancer patients (2; 4; 5; 6; 11). In the largest study to-
date of 8,160 patients with locally advanced or metastatic disease, 73% experienced 
involuntary weight loss(6). Table 1 summarises the prevalence of >5% weight loss in six 
months (a key component of the diagnostic criteria of cancer cachexia(14)) according to 
tumour site in the scientific literature.  Weight loss has consistently been shown to be most 
frequent in patients with cancers in the upper gut and lung(15; 16; 17; 18; 19). 
 
Table 1. Prevalence of patients with >5% weight loss in less than 6 months according to 
primary tumor location in the scientific literature. 
 
Primary Cancer Percentage with >5% weight loss in 
6 months. 
Pancreatic (15; 16) 41-53% 
Colorectal (20; 21; 22) 32-48% 
Gastric(23; 24) 42-75% 
Oesophageal(25) 33% 
Lung(22; 26) 44-49% 
Breast(22) 24% 
 
Despite the fact that the majority of patients present with involuntary weight loss at the 
time of diagnosis(6), in the era of obesity, patients may not appear malnourished and many 
in fact are well-nourished according to international standards(27).  Recent studies have 
reported that between 40-60% of patients with cancer are overweight or obese (BMI > 
25kg/m2) even in the setting of metastatic disease(6; 28; 29; 30; 31).  In a recent pooled analysis 













were shown to be overweight or obese at the time of enrolment (i.e. cancer diagnosis)(32).  
However, the simple measure of body mass index (BMI) or percentage weight loss does not 
capture abnormal  body composition, including muscle mass(27).  The most clinically relevant 
phenotypic feature of cancer cachexia is muscle loss and identifying those with low muscle 
mass can becomes a huge challenge in patients with overweight or obesity (11).  
Although low muscle mass is a symptom commonly associated with cancer, it is 
important to note that cancer is a disease associated with aging, therefore the aetiology of 
muscle loss in these patients can be two-fold. First resulting from the age-related decline in 
muscle mass and second due to cytokine-mediated degradation of muscle and adipose 
depots, hypermetabolism and anorexia associated with cancer cachexia(13). As such, 
distinguishing the exact cause of muscle loss can be difficult.  
 
Muscle mass 
Advancements in image-based technologies including computed tomography (CT) 
that allows the precise quantification of both muscle and adipose tissue has led to a large 
volume of research which has increased our understanding of the importance of abnormal 
body composition phenotypes, such as low muscle mass (sarcopenia), and more recently 
low muscle attenuation (MA) as important prognostic indicators of unfavourable outcomes 
in patients with cancer(6; 33; 34; 35).  Reduced skeletal muscle attenuation (radiodensity) is 
indicative of intramuscular adipose tissue infiltration and therefore poor ‘quality’ skeletal 
muscle(36).  
Low muscle mass is now known to relate to asthenia, fatigue, impaired physical 
function, increased chemotherapy toxicity, impaired quality of life (QoL) and reduced 
survival(6; 10; 27; 37).  Recent studies have shown that cancer, and its treatment, exacerbate 
muscle loss and that patients continually lose muscle mass while on treatment(35; 38; 39).  
While healthy adults over the age of forty have been shown to lose muscle at a rate of 1-
1.4% per year,(40) patients  with cancer have been shown to have a 24-fold higher rate of 
muscle loss than that observed in health aging adults(20; 38). In studies examining the rate of 
muscle loss per 100 days, rates of 3.9% have been reported in foregut cancer(38), 3.1% in 
pancreatic cancer(41) 3.3% in metastatic melanoma(35) and 5.2% in ovarian cancer(39). 
 













The prevalence of cancer cachexia and low muscle mass can vary widely depending 
on the method of assessment and diagnostic criteria used(36). From the literature, it can be 
estimated that the prevalence of cancer cachexia (based on past 6 months weight loss >5% 
as per latest consensus definition(14)) can vary between 24-75%% depending on tumor site 
(table 1), and between 38-70% of patients are considered to have low muscle mass (i.e. 
sarcopenia, based on 3 of the most commonly used diagnostic criteria).  The prevalence of 
low muscle mass is highest in lung (median 70%, range 47-79%)(42; 43; 44; 45) and pancreatic 
cancer (median 56%, range 44-89%)(16; 41; 46; 47; 48; 49; 50; 51; 52) however it is noteworthy that 
the majority of studies report a prevalence of above 40% at most other sites in the body 
(see table 2).  
 
Table 2. Prevalence of sarcopenia in patients with cancer according to the primary tumor 
location in the literature (all stages) 
Prevalence of sarcopenia defined using three of the most common definitions for defining low muscle mass is 
displayed in table 2. These definitions are as follows;  
 Prado et al. (2008)
(122)








 in women 
 Martin et al. (2013)
(29)




in men with a BMI <25 kg/m
2




in men with 
a BMI >25 kg/m
2





 Baumgartner et al. (1998)
(125)
 converted DXA cut points by Mourtzakis et al. (2008)
(126)















% with sarcopenia,  
median (range) 
Colorectal  Stage I-IV (20; 34; 53; 54; 55; 56; 57; 58; 59; 60; 61; 62; 63; 64; 
65; 66; 67; 68; 69) 
49% (20-80%) 
Esophagus Stage I-IV (70; 71; 72; 73; 74; 75; 76; 77; 78; 79; 80; 81) 53% (16-75%) 
Gastric Stage I-IV (82; 83; 84; 85; 86; 87) 47% (23-70%) 
Lung Stage I-IV (42; 43; 44; 45) 70% (47-79%) 
Kidney Stage I-IV (88; 89; 90; 91; 92; 93; 94; 95) 53% (29-90%) 
Pancreatic Stage I-IV (16; 41; 46; 47; 48; 49; 50; 51; 52) 56% (44-89%) 
Liver Stage I-IV (96; 97; 98; 99; 100) 54% (28-76%) 
Breast Stage I-IV (101; 102; 103; 104; 105; 106; 107) 38% (14-67%) 
Ovarian Stage I-IV (39; 108; 109) 47% (45-50%) 
Melanoma Stage I-IV(35; 110) 44% (24-63%) 
Bladder Stage I-IV (111; 112; 113; 114; 115) 48% (33-69%) 
Prostate Stage I-IV (116; 117) 52% (47-56%) 
Head & 
Neck 
Stage I-IV(118) 64% 
Lymphoma Stage I-IV(119; 120; 121) 51% (47-55%) 













The rates of low muscle mass seen in cancer populations are of huge public health 
importance, given that cancer cachexia and sarcopenia have been reported to be 
unequivocally associated with negative clinical outcomes in patients with cancer including 
poorer tolerance to anti-cancer treatment, poorer overall quality of life, increased risk of 
post-operative complications and poorer overall survival(6; 10; 36; 37). 
 
Impact of malnutrition on tolerance to systemic chemotherapy 
Chemotherapy can often be associated with severe toxicity that can result in dose 
delays, dose reductions and treatment termination, referred to as dose limiting toxicities 
(DLT). Severe toxic events can result in hospitalisations and can even be life threatening. 
Recent evidence suggests that variability in body composition of patients with cancer may 
be a source of disparities in the metabolism of cytotoxic agents resulting in increased 
toxicity(61; 62; 63).  
To date, in excess of 40 studies have examined the relationship between low lean 
mass (sarcopenia) and the prevalence of dose limiting toxicity in patients with cancer (see 
summary of studies in table 3).  The relationship between low lean mass and increased 
toxicity to chemotherapy has been shown to be true even in both early and late stage 
disease irrespective of the cancer site and type of systemic chemotherapy (cytotoxic single 
agents, regimens, targeted agents and immunotherapies)(75; 82; 106; 122). Although the 
relationship between low lean mass and poorer tolerance to treatment has been observed 
in the majority of studies, few smaller studies have reported no association(20; 50; 72; 95; 123; 127; 
128; 129).  
Increased toxicity in patients with low lean mass may be attributed to alterations in 
the distribution, metabolism and clearance of systemic chemotherapy drugs(102). 
Chemotherapy is traditionally dosed according to body surface area (BSA) but its use has 
been criticised in the dosage of medications with a narrow therapeutic index, such as 
chemotherapy. A four to ten-fold variation in drug clearance has been shown in individuals 
with similar BSA and there is growing concern that this approach to dosing is invalid(130; 131).  
Its continued use relies on the lack of other more precise methods for dose 
individualisation(132).    
If body weight comprises two major components (lean and fat mass) then these are 













variability in individual lean mass or fat mass may lead to changes in the volume of 
distribution of drugs and therefore adversely affect the tolerance of cytotoxic drugs(36). 
Tolerance is further compromised in individuals with sarcopenic obesity where the 
combination of excessive fat mass and diminished lean mass may significantly impact the 
tolerance of hydrophilic drugs by resulting in a disproportionally small volume of drug 
distribution in relation to their body weight or body surface area(102; 133). Variations in lean 
and fat mass can therefore lead to considerable variation in the milligram of chemotherapy 
drug per kilogram lean mass with higher doses per kilogram lean mass shown to be 
associated with more frequent and severe toxic side effects(133; 135; 136).  Pharmacokinetic 
data have supported this hypothesis, with patients with low lean mass experiencing higher 
plasma concentrations of antineoplastic drugs and experiencing more toxicity(96; 137).  For 
lipophilic drugs such as doxorubicin or trabectedin, individuals with a low-fat mass may also 
present with toxicity due to a reduced volume of distribution(134).  
In addition to the argument that pharmacokinetic parameters can explain the higher 
risk of toxicity in patients with low lean mass it is also important to note that these patients 
are excessively fragile and highly susceptible to acute medical events that exacerbate 
chemotherapy-related toxicity(91).  Systemic inflammation has been shown to decrease liver 
cytochrome activities and drug clearance and may modify drug exposure.  Low 
concentrations of circulation plasma proteins (e.g. albumin) may also affect the distribution 
of highly protein -bound drugs such as Vantetanib, sorafenib and epirubicin(96; 134; 137).  
Future clinical trials investigating dosing chemotherapy drugs according to individual body 














Table 3. Summary of studies examining the impact of computed tomography assessed skeletal muscle (at 
the third lumbar vertebrae) and treatment related toxicity in patients with cancer. 
 Stage/n Treatment Summary of findings 
Breast Cancer    
Prado et al. 2009(102) Metastatic/55 Capecitabine DLT ↑ in sarcopenic pts (50% vs. 20%, p=0.03) 




LM was lower in pts with toxicity (41.6 kg vs. 56.2 
kg, p=0.002) 







Gr 3-4 toxicity ↑ in sarcopenic pts (57% vs. 18%, 
p=0.02) and ↑ in treatment related 
hospitalisations (39% vs. 0%, p=0.005) 





Every 5 unit decrease in SMI was associated with 
increased risk of gr 3-4 toxicity (RR 1.29 (95% CI 
1.10-1.53), p=0.002) 
Mazzuca et al. 
2018(104) 
Stage I-III/21 Anthracyclines 
Lower baseline SMI was associated with Gr 3-4 vs. 
Gr 0-2 toxicities (33.4 cm2/m2 (31.1–39.9) vs 40.5 
cm2/m2 (33.4–52.0), p = 0.028).  
Colorectal Cancer    
Prado et al. 2007(133) Stage II-III/62 5-FU 
Drug dose >20mg/kg LM associated with increased 
toxicity (93% vs. 52%, p=0.005) 
Barret et al. 2013(68) Metastatic/51 
Fluoropyrimidine 
(FP)+Oxaliplatin;  
FP+ Irinotecan; FP 
Alone; Irinotecan 
without FP 
Sarcopenia independently associated with ↑ risk 
of gr 3-4 toxicity (OR: 13.55, p=0.043) 
Ali et al. 2015(140) Stage I-IV/138 FOLFOX 
Pts with the highest tertile of drug dose per kg LM 
experienced more DLT compared with those in the 
lowest tertile of drug dose (39.9% vs. 8.3%, p<0.01) 







Toxicity ↑ in sarcopenic pts (57% vs, 26%, p=0.004) 
Blauwhoff- 





Sarcopenia was not associated with ↑ toxicity 
Cespedes et al. 
2017(141) 
Non-metastatic/533 FOLFOX  
Lowest tertile of lean mass associated with early 
treatment discontinuation (OR 2.34, p=0.03), 
treatment delay (OR 2.24, p=0.002) and dose 
reduction (OR 2.28, p=0.01) 
Lung Cancer    
Arrieta et al. 2015(43) Metastatic/84 Afatinib 
Patients with lower LM and BMI <25kg/m2 
developed more DLT than patients with  higher LM 
and BMI >25 kg/m2 (71.4% vs. 18.8%, p=0.0017) 







Higher doses of gemcitabine per kg LM were 
independently associated with gr 3-4 
haematological toxicity in multivariate analyses 
(OR 1.15, 95% CI: 1.01-1.29, p=0.018), as were also 
higher doses of vinorelbine per kg LBM. 
Srdic et al. 2016(128) Advanced/100 
Platinum-doublet 
therapy 
Cachexia and sarcopenia were not found to be 
predictors of chemotoxicity  


















haematological toxicity. For doses >20% above or 
below the mean, the risk of gr 3-4 haematological 
toxicity was almost doubled (OR 1.93 (95% CI:1.21-
3.10) and halved (OR 0.52 (95% CI: 0.32-0.83) 
respectively. 
Esophagogastric cancer   
Yip et al. 2014(72) Stage I-III/35 
5FU; Platinum/5-
FU; ECX/ECF 
Sarcopenia was not associated with ↑ toxicity or 
treatment dose reduction.  









Resectable/72 Cisplatin, 5-FU 
Patients with a DLT had lower SMM than those 
without DLT (47 kg vs. 51 kg, p=0.04). Sarcopenic 
obesity associated with increased risk of DLT (OR 
5.54, 95% CI: 1.12-27.44, p=0.04) 





DLT ↑ in sarcopenic pts (65% vs. 39%, p=0.181) 





Gr 2-4 neuropathy ↑ in patients with sarcopenic 
obesity (OR 3.82, 95% CI: 1.20-12.18, p=0.024)  
Pancreatic Cancer    
Rollins et al. 2015(50) Advanced/228 Gemcitabine  
Sarcopenia was not associated with rates of 
completion of palliative chemotherapy 
Kurita et al. 2019(143) Advanced/82 FOLFIRINOX 
Gr 3-4 hematologic toxicity was ↑ in sarcopenic 
obese patients (p=0.008) 
Renal Cell 
Carcinoma 
   
Antoun et al. 
2010(144) 
Metastatic/55 Sorafenib 
DLT was most common (41%) in sarcopenic 
patients whose BMI was <25 kg/m2 and least 
common (13%) in patients who were not 
sarcopenic and/or overweight or obese (p = 0.03). 
Huillard et al. 
2013(92) 
Metastatic/61 Sunitunib 
Sarcopenic pts with a BMI< 25 kg/m2 experienced 
↑ DLTs (OR 4.1, 95% CI: 1.3-13.3), ↑ cumulative gr 
2 or 3 toxicities (p=0.008), ↑ grade 3 toxicities 
(p=0.04) and ↑ acute vascular toxicities (p=0.009). 
Cushen et al. 
2017(89) 
Metastatic/55 Sunitunib 
Pts with the lowest compared with the highest 
measurements of LM experienced more DLT (92% 
vs. 57%, p=0.05) 
Auclin et al. 2017(95) Metastatic/124 Everolimus SMI was not associated with ↑ toxicity 
Melanoma    





Sarcopenia and overweight (BMI >25kg/m2) 
women had a 6.5 fold ↑  risk of toxicity. 
Daly et al. 2017(35) Metastatic/84 Ipilimumab 
Sarcopenic was associated with ↑ high grade 
adverse events (OR 5.34, p=0.033) 
Hepatocellular carcinoma   
Mir et al. 2012(96)  Advanced/40 Sorafenib DLT ↑ in sarcopenic pts (82% vs. 31%, p=0.005) 
Nault et al.  2015(100) Advanced/52 
Sorafenib, 
Brivanib 
Sarcopenia was associated with a greater rate of 
hand-foot syndrome (p=0.049) 
Other Cancer Sites    













 Stage/n Treatment Summary of findings 
2012(127) sites/Advanced/48 infusion 






Gr 1-2 toxicity ↑ in sarcopenic pts (100% vs. 
73.7%) 












Temsirolimus Sarcopenia was not associated with ↑ toxicity 
Cousin et al. 
2014(147) 
Mixed cancer sites/ 
Stage I-IV/93 
Phase 1 drugs 
Severe toxic events were observed in 25.5% of the 
pts when the SMI was below the median value 
compared to 6.5% of patients with a high SMI 
(p = 0.02) 





LM alone was not predictive of DLT. A lower 
FM/LBM ratio was the most powerful variable 
associated with toxicity (p=0.006) 





Sarcopenia and low MA associated with ↑DLT 
toxicity 





Sarcopenia was independently associated with ↑ 
risk of febrile neutropenia hospitalization (OR 1.64, 
95% CI: 1.01-2.65) and ↓ completion of standard 
treatment cycles (OR 1.49, 95% CI: 1.02-2.16) 






Patients with low skeletal muscle mass 
experienced more DLT more frequently than 
patients with normal skeletal muscle mass (44.3% 
vs. 13.7%, p<0.001) 





Muscle parameters were not associated with ↑ 
toxicity 
DLT, Dose limiting toxicity; Pts, patients; LM, lean mass; Gr, Grade; SMI, Skeletal muscle index; CI, confidence 
interval; OR, odds ratio; RR, relative risk; mg, milligrams; kg, kilograms; 5-FU, 5-Flurouracil; BMI, body mass 
index; HCC, hepatocellular carcinoma; GI, gastrointestinal. 
 
 
Impact of malnutrition on performance status and quality of life 
Quality of life (QoL) in patients with cancer is a subjective multidimensional construct that 
represents the patient’s psychological well-being, functional status, health perceptions, and 
disease- and treatment- related symptoms.  It is now universally accepted that QoL is the central 
tenet in cancer care, especially in those patients with incurable disease.  
Weight loss and malnutrition has been shown to have profound negative effects on QOL in 
patients with cancer.  A recent systematic review examining the impact of weight loss on QoL in 
patients with cancer reported a negative correlation between weight loss and QoL in 23 out of 27 













major cause of fatigue(149; 150), reduced functional ability(151)  and a source of emotional distress(149; 
152).   
Inconsistent reports on the relationship between muscle parameters and QoL have been 
published in the literature(127; 153; 154; 155).  Parsons and colleagues reported no significant 
associations between low muscle mass, and symptom burden or functional life domains assessed 
by the MD Anderson Symptom Inventory, in a cohort of 104 patients with advanced cancer(127). 
However, in a study of 734 patients with advanced lung cancer, low muscle mass was non-linearly 
associated with lower global QoL, physical function and role function, and associated with more 
symptoms (fatigue and pain), while low MA was associated with poor physical function and more 
dyspnoea(155). Low muscle mass has also been associated with greater depression symptoms and 
more fatigue in patients with advanced cancer(153; 154). 
The mode by which weight loss exerts its influence on QoL is not fully understood but may 
relate to muscle atrophy associated with cachexia and weight loss leading to fatigue or reduced 
functional capacity.  Recent work has suggested that the complex interplay between metabolic 
disruption and pro-inflammatory cytokines  (i.e. IL-6, IL-8 and TNF-α) in cancer cachexia often leads 
to physical, biochemical and nutritional deterioration which subsequently leads to poor QoL(156). 
Systemic inflammation and loss of muscle is also thought to drive cancer related fatigue, which is 
thought to affect up to 80% of patients(157) both during and after treatment cessation(157; 158; 159; 160).  
Severe and persistent fatigue, along with muscle wasting has been shown to inhibit QoL by 
considerably reducing functional capacity to fully participate in daily living tasks(157).   Also, evidence 
from a variety of preclinical and clinical studies suggest that systemic inflammation has a direct role 
in the development of cancer associated symptom clusters including pain, fatigue, mood, anorexia 
and physical function(161). Systemic inflammation has been shown to be associated with poorer QoL 
even in those with a good performance score(162). 
  
Importantly, interventions aimed at targeting nutritional status and attenuating weight loss 
have proven successful in improving aspects QoL in patients with cancer(163). In addition, novel 
cachexia treatments, such as Anamorelin, an oral ghrelin-receptor agonist with appetite enhancing 
and anabolic activity have shown a favourable clinical response in alleviating anorexia-cachexia 
symptoms(26). Research is warranted to determine if attenuating the systemic inflammatory 
response leads to clinically relevant improvements in symptoms, which may represent a new 














Impact on survival  
Over the past decade, an array of studies have examined the relationship between the 
presence of low muscle mass (sarcopenia) and its impact on survival in patients with cancer. Most 
studies report a significant decrease in overall survival in patients with low muscle mass compared 
with their counterparts, irrespective of the primary cancer site and stage (see Figure 1). Figure 1 
displays the risk of mortality [adjusted HR (95% CI)] in sarcopenic patients compared with non-
sarcopenic patients according to primary tumour location.  
The relationship between low muscle mass and poor survival has been the topic of various 
systematic reviews and meta-analysis(164; 165; 166; 167).  In a recent systematic review and meta‐
analysis of 38 studies that included 7,843 patients with solid tumours, low muscle cross‐sectional 
area was observed in 27.7% of patients with cancer and associated with poorer overall survival [HR: 
1.44, 95% CI: 1.32–1.56], cancer‐specific survival [HR: 1.93, 95% CI: 1.38–2.70,], as well as disease‐
free survival [HR: 1.16, 95% CI: 1.00–1.30] but not with progression free survival (HR: 1.54, 95% CI: 
0.90-2.64)(165).  This meta-analysis demonstrated that the adverse effects of low muscle mass on 
overall survival were similar in both metastatic [HR: 1.37, 95% CI: 1.21–1.56] and non‐metastatic 
disease [HR: 1.54, 95% CI: 1.31–1.79], and this relationship was observed across different primary 
tumour sites. Recently, in two of the largest observational cohort studies to date, Caan and 
colleagues(168; 169) demonstrated the prognostic value of low muscle mass in non-metastatic breast 
(n=3,241) and colorectal cancer (n=3,262). Low lean mass was present in 34 and 42% of patients, 
respectively, and was independently associated with a 27–41% higher risk of overall mortality 
[colon: HR 1.24, (95% CI: 1.09-1.48); breast: HR 1.41 (95% CI: 1.18-1.69)] (168; 169). 
In addition to low muscle area (sarcopenia), low muscle attenuation (radiodensity) 
(indicative of fatty infiltration of muscle tissue) is also associated with poorer survival in a variety of 
tumours including non-small cell lung cancer, colorectal, endometrial, renal and ovarian cancer (170) 
(171; 172; 173) (174), (109; 175), (176).  Importantly, in some cases, low MA appears to superior in predicting 
mortality compared with low lean mass alone (87; 107; 170; 177; 178). In a cohort of 1,681 early stage 
colorectal cancer (CRC) patients, low MA was associated with higher all-cause mortality [HR 1.91 
(95% CI: 1.53-2.38)] (173). Ataseven et al.(109)  reported that in patients with advanced epithelial 
ovarian cancer receiving primary debulking surgery (n=323), low MA (<32 HU) was associated with 
a significantly reduced overall survival compared with patients with a higher MA (median survival 













regression analysis (HR 1.79 (95% CI: 1.22-2.62). In another cohort of patients with early stage CRC 
(n=3,262), low MA has also been described as an important predictor of mortality [HR 1.61 (95% CI: 
1.36-1.90)] and CRC-specific mortality [HR 1.74 (95% CI: 1.38-2.21)]. Of note, in this study, patients 
with both low muscle mass and low MA were at the highest risk of overall [HR: 2.02 (95% CI: 1.65-
2.47)] and cancer-specific mortality [HR: 2.54 (95% CI: 1.91-3.37)](171). It has also been 
demonstrated that the risk of mortality associated with low muscle mass and low MA can be 
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Loss of muscle during treatment & survival 
Notwithstanding the impact of low muscle mass on survival, several studies have 
emphasised that patients continually lose muscle while on treatment and that this is associated 
with an increased risk of mortality in a number of cancers. Patients with advanced pancreatic 
cancer (n=97) who experienced early loss of skeletal muscle (>10% within 3 months of diagnosis) 
were at increased risk of poorer overall survival and progression free survival compared to patients 
who did not experience muscle loss to the same degree [HR 2.16 (95% CI: 1.23-3.78), p=0.007 and 
HR 2.31 (95% CI: 1.30-4.09), p=0.004](217). In patients with surgically resected stage I-III CRC 
(n=1924), those who experienced the largest decrease in muscle mass (≥2 standard deviations or 
the equivalent to ≥11.4% loss) and the largest decline in mean MA (≥2 SD; ≥20.2% loss) from 
baseline were at a significantly increased risk of mortality [HR 2.15 (95% CI: 1.59-2.92), p<0.001 and 
HR 1.61 (95% CI: 1.20-2.15), p=0.002, respectively], and these findings were independent of 
changes in body mass or other body composition parameters(172). To date, losses in muscle have 
been shown to be prognostic of reduced survival in pancreatic(51; 217), oesophageal, gastric(218), 
lung(219), colorectal(20; 220; 221), ovarian(39), melanoma(35) and foregut cancers(38).  
 
Conclusions 
While weight loss and malnutrition have been frequently reported in cancer patients over the past 
40 years, research over the past 15 years has unearthed the importance of low muscle mass as 
being the new face of malnutrition in oncology populations. The study of body composition in 
oncology has highlighted the importance of both low muscle mass and low muscle attenuation 
which are associated with poorer tolerance to chemotherapy; significant deterioration in a 
patients’ performance status and quality of life, and poorer survival.  Early screening to identify 
individuals with muscle loss and decreased muscle quality would allow for earlier multimodal 













training and  optimal dietary intake and supplementation, combined with pharmacotherapy; these 
are currently the focus of randomised controlled trials(222). It remains to be seen if multimodal 
therapies can provide a sufficient stimulus to prevent or slow the cascade of tissue wasting and if 
this then impacts on outcome in a positive manner. There also exists an equal need for routine, 
cost-efficient, and feasible methods to quantify muscle and adipose tissue in clinical practice. The 
study of body composition is one of the most provocative areas in oncology that offers tremendous 
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